Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy

医学 乳腺癌 肿瘤科 内科学 化疗 新辅助治疗 三阴性乳腺癌 阶段(地层学) 肿瘤浸润淋巴细胞 癌症 免疫疗法 生物 古生物学
作者
Carsten Denkert,Gϋnter von Minckwitz,Silvia Darb‐Esfahani,Bianca Lederer,Barbara Ingold Heppner,Karsten E. Weber,Jan Budczies,Jens Huober,Frederick Klauschen,Jenny Furlanetto,Wolfgang Schmitt,Jens‐Uwe Blohmer,Thomas Karn,Berit M. Pfitzner,Sherko Kümmel,Knut Engels,Andreas Schneeweiß,Arndt Hartmann,Aurelia Noske,Peter A. Fasching
出处
期刊:Lancet Oncology [Elsevier BV]
卷期号:19 (1): 40-50 被引量:1733
标识
DOI:10.1016/s1470-2045(17)30904-x
摘要

Tumour-infiltrating lymphocytes (TILs) are predictive for response to neoadjuvant chemotherapy in triple-negative breast cancer (TNBC) and HER2-positive breast cancer, but their role in luminal breast cancer and the effect of TILs on prognosis in all subtypes is less clear. Here, we assessed the relevance of TILs for chemotherapy response and prognosis in patients with TNBC, HER2-positive breast cancer, and luminal-HER2-negative breast cancer.Patients with primary breast cancer who were treated with neoadjuvant combination chemotherapy were included from six randomised trials done by the German Breast Cancer Group. Pretherapeutic core biopsies from 3771 patients included in these studies were assessed for the number of stromal TILs by standardised methods according to the guidelines of the International TIL working group. TILs were analysed both as a continuous parameter and in three predefined groups of low (0-10% immune cells in stromal tissue within the tumour), intermediate (11-59%), and high TILs (≥60%). We used these data in univariable and multivariable statistical models to assess the association between TIL concentration and pathological complete response in all patients, and between the amount of TILs and disease-free survival and overall survival in 2560 patients from five of the six clinical trial cohorts.In the luminal-HER2-negative breast cancer subtype, a pathological complete response (pCR) was achieved in 45 (6%) of 759 patients with low TILs, 48 (11%) of 435 with intermediate TILs, and 49 (28%) of 172 with high TILs. In the HER2-positive subtype, pCR was observed in 194 (32%) of 605 patients with low TILs, 198 (39%) of 512 with intermediate TILs, and 127 (48%) of 262 with high TILs. Finally, in the TNBC subtype, pCR was achieved in 80 (31%) of 260 patients with low TILs, 117 (31%) of 373 with intermediate TILs, and 136 (50%) of 273 with high TILs (p<0·0001 for each subtype, χ2 test for trend). In the univariable analysis, a 10% increase in TILs was associated with longer disease-free survival in TNBC (hazard ratio [HR] 0·93 [95% CI 0·87-0·98], p=0·011) and HER2-positive breast cancer (0·94 [0·89-0·99], p=0·017), but not in luminal-HER2-negative tumours (1·02 [0·96-1·09], p=0·46). The increase in TILs was also associated with longer overall survival in TNBC (0·92 [0·86-0·99], p=0·032), but had no association in HER2-positive breast cancer (0·94 [0·86-1·02], p=0·11), and was associated with shorter overall survival in luminal-HER2-negative tumours (1·10 [1·02-1·19], p=0·011).Increased TIL concentration predicted response to neoadjuvant chemotherapy in all molecular subtypes assessed, and was also associated with a survival benefit in HER2-positive breast cancer and TNBC. By contrast, increased TILs were an adverse prognostic factor for survival in luminal-HER2-negative breast cancer, suggesting a different biology of the immunological infiltrate in this subtype. Our data support the hypothesis that breast cancer is immunogenic and might be targetable by immune-modulating therapies. In light of the results in luminal breast cancer, further research investigating the interaction of the immune system with different types of endocrine therapy is warranted.Deutsche Krebshilfe and European Commission.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
ly楠发布了新的文献求助10
1秒前
1秒前
2秒前
4秒前
郝飞飞完成签到,获得积分10
4秒前
qqz完成签到,获得积分10
5秒前
花花应助淡淡蛋挞采纳,获得10
6秒前
华仔应助虚幻靖易采纳,获得10
6秒前
7秒前
yingying发布了新的文献求助10
8秒前
可爱的函函应助香蕉静芙采纳,获得10
9秒前
张浩发布了新的文献求助10
9秒前
10秒前
fei发布了新的文献求助150
10秒前
11秒前
11秒前
12秒前
依灵完成签到,获得积分10
12秒前
12秒前
充电宝应助mariawang采纳,获得10
13秒前
王哈哈关注了科研通微信公众号
14秒前
kkdkg发布了新的文献求助10
14秒前
时笙发布了新的文献求助10
14秒前
苏利文完成签到,获得积分10
15秒前
15秒前
小二郎应助尔尔采纳,获得30
15秒前
16秒前
小丑鱼儿发布了新的文献求助10
16秒前
17秒前
Rubby应助Sissi采纳,获得10
17秒前
18秒前
隐形夕阳发布了新的文献求助50
19秒前
搞学术的发布了新的文献求助10
19秒前
Freddie发布了新的文献求助10
21秒前
淡淡梦容发布了新的文献求助10
21秒前
21秒前
mmol发布了新的文献求助10
22秒前
可靠的冰烟完成签到,获得积分10
22秒前
Ava应助kkdkg采纳,获得10
23秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
‘Unruly’ Children: Historical Fieldnotes and Learning Morality in a Taiwan Village (New Departures in Anthropology) 400
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
基于可调谐半导体激光吸收光谱技术泄漏气体检测系统的研究 350
Robot-supported joining of reinforcement textiles with one-sided sewing heads 320
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3988732
求助须知:如何正确求助?哪些是违规求助? 3531027
关于积分的说明 11252281
捐赠科研通 3269732
什么是DOI,文献DOI怎么找? 1804764
邀请新用户注册赠送积分活动 881869
科研通“疑难数据库(出版商)”最低求助积分说明 809021